Thalidomide: Therapeutic potential in hematologic malignancies

[1] Anderson KC, 1999, SEMIN HEMATOL, V36, P3

[2] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) : 1827 - 1834

[3] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 4082 - 4085

[4] Eisen T, 1998, P AN M AM SOC CLIN, V17, P441

[5] Figg WD, 1997, P AN M AM SOC CLIN, V16, p333a

[6] FINE HA, 1997, P AN M AM SOC CLIN, V16, pA385

[7] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31

[8] Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J]. IMMUNOPHARMACOLOGY, 1996, 31 (2-3): : 213 - 221

[9] Thalidomide on the comeback trail [J]. NATURE MEDICINE, 1999, 5 (05) : 489 - 490

[10] Current drug therapy for multiple myeloma [J]. DRUGS, 1999, 57 (04) : 485 - 506

[1] Anderson KC, 1999, SEMIN HEMATOL, V36, P3

[2] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) : 1827 - 1834

[3] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 4082 - 4085

[4] Eisen T, 1998, P AN M AM SOC CLIN, V17, P441

[5] Figg WD, 1997, P AN M AM SOC CLIN, V16, p333a

[6] FINE HA, 1997, P AN M AM SOC CLIN, V16, pA385

[7] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31

[8] Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J]. IMMUNOPHARMACOLOGY, 1996, 31 (2-3): : 213 - 221

[9] Thalidomide on the comeback trail [J]. NATURE MEDICINE, 1999, 5 (05) : 489 - 490

[10] Current drug therapy for multiple myeloma [J]. DRUGS, 1999, 57 (04) : 485 - 506